Brief: Basilea Pharmaceutica H1 Revenue Up At CHF 104.0 Mln

Basilea Pharmaceutica AG, Allschwil

19/08/2025 06:18

Aug 19 (Reuters) - BASILEA PHARMACEUTICA BSLN.S:

H1 OPERATING EXPENSES CHF -79.9 MILLION

H1 PRETAX PROFIT CHF 19.3 MILLION

H1 EPS CHF 1.26

H1 OPERATING INCOME CHF 24 MILLION

H1 BASIC EPS CHF 1.29

H1 NET INCOME CHF 15.8 MILLION

H1 TOTAL REVENUE GROWS SIGNIFICANTLY BY 36% TO CHF 104.0 MILLION

FULL-YEAR 2025 GUIDANCE: ON TRACK AND UPDATED TO REFLECT RECENT IN-LICENSING OF A NOVEL ORAL PHASE 3-READY ANTIBIOTIC

OUTLOOK 2025: TOTAL REVENUE IS EXPECTED TO INCREASE BY 8% TO CHF 225 MILLION

OUTLOOK 2025: EXPECTED 14% INCREASE IN ROYALTY INCOME TO CHF 110 MILLION

EXPECT TO MAINTAIN A HIGH OPERATING PROFIT LEVEL OF CHF 50 MILLION IN 2025

Source text: ID:nGNE8yBVgT

Further company coverage: BSLN.S

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))